NASDAQ:MYGN has been receiving an average rating of ‘Hold’ from around eleven analysts who were covering this company. According to MarketBeat, three of the analysts covering it have rated their stocks with a ‘sell’. Around five of them have recommended ‘hold’, while a lone analyst recommended ‘Strong buy’. The average price target for 12 months has been set by the brokerages at around $16.29.
Several analysts have commented on the shares of MYGN. Needham and Company LLC mentioned a ‘hold’ on the Myriad Genetics (NASDAQ:MGYN)- something they reiterated in a research note that was dated August 14th. BidaskClub, on the other hand, started upgrading the shares from ‘sell’, to ‘hold’. ValuEngine, too, upgraded the shares of NASDAQ:MYGN from ‘buy’ to ‘strong buy’.
The Quarterly Earnings of NASDAQ:MYGN
The NASDAQ:MYGN started off at $12.07 on Thursday. The company experiences a 52-week low of $9.24, along with a 52 week high of $35.29. The market capitalization for this stock has been set at $976.45 million, with a beta of 1.43, and a P/E ratio of -4.88. The debt-to-equity ratio of this company is 0.24, the current ratio is 2.26, while the quick ratio is 2.06. The 200 day simple moving average for the company is $13.35, while the 50 day simple moving average is fixed at $13.22.
NASDAQ:MYGN recently released the quarterly results of earnings on the 13th of August. The company’s report stated that the earnings/share had been $0.31, which hit the consultants’ estimates of $0.47. The revenue was around $93.20 million this quarter, which went up against the consensus estimate of $95.44. The NASDAQ:MYGN had quite a negative net margin of around 31.24%, which a return of equity set at 2.69%. The company had earned around $0.42 EPS last year at the same time. On an average, the analysts have forecasted that NASDAQ:MYGN would be posting around -0.54 EPS in this year.
Recently, the COO of NASDAQ:MYGN, Alexander Ford sold around 2,804 shares of the company’s stock in a Tuesday transaction. These shares were sold out at a price of $13.78- which put the total transaction at $38,639.12.
Myriad Genetics (NASDAQ:MYGN) Company Profile
NASDAQ:MYGN is first, and foremost a company investing in molecular diagnosis. Along with this, the company also develops, predicts markets, personalizes, and prognoses medical tests both in the United States, and the entire world. The company has been known to offer myRisk Hereditary Cancer tests- which is simply a DNA sequencing test. It also offers BRACAnalysis- a DNA Sequencing test which assesses the risk of ovarian and breast cancer.
The analysts’ consensus recommendation might put NASDAQ:MYGN in a spot of bother over the coming weeks if they are not careful with how they work their shares.